| Autor: |
Waalboer-Spuij, Rick, Holterhues, Cynthia, van Hattem, Simone, Schuttelaar, Marie Louise a., Gaastra, Menno T.W., Kuijpers, Daniëlle I.M., Hollestein, Loes M., Nijsten, Tamar E.C. |
| Zdroj: |
Dermatology (10188665); Jun2015, Vol. 231 Issue 1, p56-62, 7p, 4 Charts, 1 Graph |
| Abstrakt: |
Objective: To document the impact on patient-reported outcomes and health-related quality of life (HRQoL) of treatment with imiquimod cream in patients with actinic keratosis (AK) and superficial basal cell carcinoma (sBCC). Methods: This open-label, multicenter study included AK and sBCC patients eligible for treatment with imiquimod 5% cream. HRQoL was measured by the Skindex-17 and the Skin Cancer Index (SCI) and treatment satisfaction by the Treatment Satisfaction Questionnaire for Medication. Results: 118 AK patients and 84 patients with sBCC were included. Low baseline HRQoL impairment was found on both questionnaires, which remained low after treatment, except for a small dip at the end of the application period. Conclusion: Imiquimod 5% cream treatment has no clinically relevant HRQoL impact in AK and sBCC patients according to the Skindex-17 and SCI. The effect of imiquimod treatment on HRQoL may be limited or these questionnaires do not fully capture relevant issues, such as fear of recurrence. © 2015 S. Karger AG, Basel [ABSTRACT FROM AUTHOR] |
| Databáze: |
Complementary Index |
| Externí odkaz: |
|
